HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction
Alin L Girnita, Rene Duquesnoy, Samuel A Yousem, Aldo T Iacono, Timothy E Corcoran, Manuela Buzoianu, Bruce Johnson, Kathy J Spichty, James H Dauber, Gilbert Burckart, Bartley P Griffith, Kenneth R McCurry, Adriana Zeevi, Alin L Girnita, Rene Duquesnoy, Samuel A Yousem, Aldo T Iacono, Timothy E Corcoran, Manuela Buzoianu, Bruce Johnson, Kathy J Spichty, James H Dauber, Gilbert Burckart, Bartley P Griffith, Kenneth R McCurry, Adriana Zeevi
Abstract
Bronchiolitis obliterans syndrome (BOS) represents a major limitation in lung transplantation. While acute rejection is widely considered the most important risk factor for BOS, the impact of HLA-specific antibodies is less understood. Of 51 lung recipients who were prospectively tested during a 4.2 +/- 1.6-year period, 14 patients developed HLA-specific antibodies. A multi-factorial analysis was performed to correlate the prevalence of BOS with HLA antibodies, persistent-recurrent acute rejection (ACR-PR), lymphocytic bronchiolitis, and HLA-A, -B, and -DR mismatches. HLA-specific antibodies were associated with ACR-PR (10/14 vs. 11/37 with no antibodies, p < 0.05), lymphocytic bronchiolitis (8/14 vs. 10/37, p < 0.05), and BOS (10/14, vs. 9/37, p < 0.005). Other risk factors for BOS were: lymphocytic bronchiolitis (13/18 vs. 6/33 with no lymphocytic bronchiolitis, p < 0.0001), ACR-PR (12/21 vs. 7/30 with no ACR-PR, p < 0.05), and the number of HLA-DR mismatches (1.7 +/- 0.48 in BOS vs. 1.2 +/- 0.63 without BOS, p < 0.05). The presence of antibodies exhibited a cumulative effect on BOS when it was associated with either lymphocytic bronchiolitis or ACR-PR. The complex relationship between the development of HLA antibodies and acute and chronic lung allograft rejection determines the importance of post-transplant screening for HLA-specific antibodies as a prognostic element for lung allograft outcome.
Source: PubMed